UPDATE: FDA Grants Fast Track Designation to Johnson & Johnson’s Investigational Therapy, Nipocalimab, for Adults with Systemic Lupus Erythematosus

The Fast Track designation was supported by positive topline results from its Phase 2b JASMINE study.

This post was originally published on this site